Poor treatment tolerance in head and neck cancer patients with low muscle mass

Background We ascertain the role of a low cervical paraspinal skeletal muscle index (CPSMI) as a biomarker for poor treatment tolerance in patients with operable mucosal head and neck squamous cell carcinoma (HNSCC). Methods A prospective cohort of patients with operable HNSCC requiring microvascula...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck 2022-04, Vol.44 (4), p.844-850
Main Authors: Mascarella, Marco A., Patel, Terral, Vendra, Varun, Gardiner, Lauren, Kergoat, Marie‐Jeanne, Kubik, Mark W., Solari, Mario G., Snyderman, Carl H., Traylor, Katie S., Ferris, Robert L., Kim, Seungwon, Duvvuri, Umamaheswar, Sridharan, Shaum S.
Format: Article
Language:English
Subjects:
Computed tomography
delay to adjuvant therapy
Head & neck cancer
head and neck cancer
Head and neck carcinoma
Head and Neck Neoplasms - diagnostic imaging
Head and Neck Neoplasms - surgery
Humans
Microvasculature
Middle Aged
Morbidity
Mucosa
Muscle, Skeletal - diagnostic imaging
Patients
Prospective Studies
Retrospective Studies
Sarcopenia
Sarcopenia - complications
Skeletal muscle
Squamous cell carcinoma
Squamous Cell Carcinoma of Head and Neck - pathology
treatment tolerance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background We ascertain the role of a low cervical paraspinal skeletal muscle index (CPSMI) as a biomarker for poor treatment tolerance in patients with operable mucosal head and neck squamous cell carcinoma (HNSCC). Methods A prospective cohort of patients with operable HNSCC requiring microvascular reconstruction was evaluated. Low CPSMI was calculated using preoperative CT neck imaging. Poor treatment tolerance, a composite measure of incomplete therapy or severe morbidity/mortality during treatment, was the primary outcome. Results One hundred and twenty‐seven patients underwent extirpative surgery with a mean age was 60.5. Poor treatment tolerance occurred in 71 (56%) patients with 21 not completing recommended adjuvant therapy and 66 having severe treatment‐related morbidity. A low CPSMI was independently associated with poor treatment tolerance (OR 2.49, 95%CI 1.10–5.93) and delay to adjuvant therapy (OR 4.48, 95%CI 1.07–27.6) after adjusting for multiple confounders. Conclusion Low CPSMI was independently associated with poor treatment tolerance in patients with operable HNSCC.
ISSN:1043-3074
1097-0347
1097-0347
DOI:10.1002/hed.26978